Longevity + SkinResearch-onlyEarly humanUpdated 2026-04-22

Peptide reference file

GHK-Cu

Trending #1 in Longevity31.7k searches/moMixed

GHK-Cu is a copper-binding tripeptide discussed in skin biology, extracellular matrix signaling, and wound-response contexts.

Current readout: early human evidence, research-only status, unclear approval state, human evidence appears in the current trail, registered trials are linked, and 4 linked sources in the seed trail.

PubChem CID 139035031 | 132 PubMed results | 2 trial records | 4 DailyMed labels | 0 Drugs@FDA applications

GHK-Cu is mostly discussed because it bridges cosmetic peptide culture and repair biology, especially around skin quality and collagen-related claims.

The public claim is straightforward: People look at GHK-Cu for skin quality, collagen, hair, wound appearance, and cosmetic repair claims. Some skin-related evidence exists, but topical/cosmetic signals should not be stretched into systemic anti-aging certainty.

In plain language, gHK-Cu binds copper and is discussed around extracellular matrix, skin repair context, and wound-response signaling.

Early humanResearch-only
Copper peptideSkin matrixWound context

Aliases: Copper tripeptide-1, Gly-His-Lys copper

SpecimenGHK-Cu specimen
CCCCCHHHHHHHCuNNO
Formula
C14H21CuN6O4-
Mass
400.90
Evidence
Early human
Elements
5

Most commonly discussed in relation to Copper peptide, Skin matrix, Wound context.

What GHK-Cu is

GHK-Cu is a copper-binding tripeptide discussed in skin biology, extracellular matrix signaling, and wound-response contexts.

GHK-Cu is grouped under Longevity + Skin on PeptideFactCheck because it bridges cosmetic peptide culture and repair biology, especially around skin quality and collagen-related claims.

The useful starting point is to separate the molecule itself from the internet story around it. The public story is that copper peptide equals skin remodeling.

Why people keep looking it up

People look at GHK-Cu for skin quality, collagen, hair, wound appearance, and cosmetic repair claims.

GHK-Cu binds copper and is discussed around extracellular matrix, skin repair context, and wound-response signaling.

GHK-Cu tends to stay in the conversation because it touches a familiar public theme: copper peptide, skin matrix, and wound context. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Some skin-related evidence exists, but topical/cosmetic signals should not be stretched into systemic anti-aging certainty.

Human cosmetic and dermatology-adjacent evidence exists, but claim quality varies heavily by formulation and endpoint.

Preclinical work explores matrix remodeling, gene-expression context, and repair signaling.

Why this page carries the current tier: Some human skin-related signal, with many claims extending beyond the evidence.

The current seed trail for GHK-Cu is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

Formulation, route, copper exposure, and leapfrogging from topical evidence to systemic claims are major issues.

Regulatory classification depends on product claims, route, and jurisdiction. It should not be treated as broadly approved for systemic optimization.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GHK-Cu. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for GHK-Cu is CID 139035031. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
139035031
Formula
C14H21CuN6O4-
Molecular weight
400.90
InChIKey
LREZPQNYQZAPJC-ACMTZBLWSA-L

Matched synonyms include Copper tripeptide, GHK-Cu, HY-P0063, EX-A13486, CS-0015088, Gly-His-Lys-Cu(II), Copper Peptide(GHK-Cu).

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for GHK-Cu returns 2 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for GHK-Cu returns 132 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Brand names
YVTYVT COPPER PEPTIDES FACIAL SERUM
Generic names
BETAINE,COPPER TRIPEPTIDE-1,ALLANTOIN,CHRYSANTHELLUM INDICUM WHOLE
Routes
EXTRACORPOREAL
Application numbers
505G(a)(3)

Indications and usage. It repairs, tightens, and combats signs of premature aging, while restoring skin’s natural density and firmness. Twice daily, morning & evening. For the best results, persist in using it

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.